- Home
- ATNF vs ENSC Comparison
ATNF vs ENSC Comparison
Compare ATNF & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- ENSC
- Stock Information
- Founded
- ATNF 2016
- ENSC 2003
- Country
- ATNF United States
- ENSC United States
- Employees
- ATNF N/A
- ENSC N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- ENSC Health Care
- Exchange
- ATNF Nasdaq
- ENSC Nasdaq
- Market Cap
- ATNF 3.8M
- ENSC 3.4M
- IPO Year
- ATNF N/A
- ENSC N/A
- Fundamental
- Price
- ATNF $1.18
- ENSC $2.34
- Analyst Decision
- ATNF
- ENSC
- Analyst Count
- ATNF 0
- ENSC 0
- Target Price
- ATNF N/A
- ENSC N/A
- AVG Volume (30 Days)
- ATNF 234.0K
- ENSC 5.0M
- Earning Date
- ATNF 05-27-2025
- ENSC 05-13-2025
- Dividend Yield
- ATNF N/A
- ENSC N/A
- EPS Growth
- ATNF N/A
- ENSC N/A
- EPS
- ATNF N/A
- ENSC N/A
- Revenue
- ATNF N/A
- ENSC $6,224,081.00
- Revenue This Year
- ATNF N/A
- ENSC N/A
- Revenue Next Year
- ATNF N/A
- ENSC N/A
- P/E Ratio
- ATNF N/A
- ENSC N/A
- Revenue Growth
- ATNF N/A
- ENSC 256.35
- 52 Week Low
- ATNF $0.66
- ENSC $1.62
- 52 Week High
- ATNF $17.75
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- ATNF 59.10
- ENSC 46.40
- Support Level
- ATNF $1.08
- ENSC $1.99
- Resistance Level
- ATNF $1.24
- ENSC $2.40
- Average True Range (ATR)
- ATNF 0.17
- ENSC 0.26
- MACD
- ATNF 0.02
- ENSC 0.02
- Stochastic Oscillator
- ATNF 54.90
- ENSC 28.00
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.